-
-
-
-
-
-
-
Dianthus Therapeutics (DNTH) Tops Q2 EPS by 77c
-
-
-
-
-
-
-
Truist on Dianthus Therapeutics (DNTH) Amid Extreme Selloff: 'we believe the readthrough to DNTH should be limited'
-
-
-
-
-
-
-
William Blair Reiterates Outperform Rating on Dianthus Therapeutics (DNTH): 'should see multiple value inflection for shares'
-
-
-
-
-
-
-
Dianthus Therapeutics (DNTH) PT Raised to $120 at Stifel
-
-
-
-
-
-
-
Dianthus Therapeutics (DNTH) PT Raised to $200 at Guggenheim
-
-
-
-
-
-
-
Truist Securities: 'Is Biotech Back?!'
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Dianthus Therapeutics (DNTH)
-
479,047 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


